newsfilter
← Latest News
GlobeNewswire·

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Pro forma cash and investment balance of